amisulpride + clozapine + olanzapine + risperidone

This is a combination of four atypical (second-generation) antipsychotic drugs—amisulpride, clozapine, olanzapine, and risperidone. Each agent acts primarily as an antagonist at dopamine D2 and serotonin 5-HT2A receptors but with distinct receptor binding profiles and side effect spectra. This combination is not a standard or approved fixed-dose product but may be used off-label in complex cases of treatment-resistant schizophrenia where monotherapy or dual therapy has failed. Clozapine is considered the gold standard for treatment-resistant schizophrenia; however, augmentation with other antipsychotics such as amisulpride, olanzapine, or risperidone may be attempted to improve efficacy or manage specific symptom domains[1][4][7]. The rationale for combining these agents includes potential additive effects on positive and negative symptoms of schizophrenia through complementary receptor activity. However, evidence supporting the efficacy and safety of such multi-drug combinations is limited; most studies focus on dual combinations (e.g., clozapine plus risperidone or amisulpride), with little data on triple or quadruple regimens[1][6][8]. Polypharmacy increases the risk of adverse effects including metabolic syndrome, extrapyramidal symptoms, sedation, cardiac effects (QT prolongation), agranulocytosis (with clozapine), and drug interactions.